Loading
A phase 3 trial of Cabozantinib, Sorafenib, Atezolizumab in hepatocellular carcinoma, run by Exelixis, active and no longer recruiting.
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy is a phase 3 interventional study registered as NCT03755791 by Exelixis, with 837 participants enrolled, started 2018-06-10 and due to reach its primary completion in 2021-11-30. Interventions recorded: Cabozantinib, Cabozantinib, Sorafenib, Atezolizumab. Conditions listed: Hepatocellular Carcinoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
837 enrolled.
99% CI 5.55 to 8.34; Figures from the ClinicalTrials.gov results section (first posted 2025-12-11), not from a publication · 99% CI 2.79 to 7.03
Source96% CI 14.46 to 18.56; Figures from the ClinicalTrials.gov results section (first posted 2025-12-11), not from a publication · 96% CI 12.19 to 19.98
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) for the Experimental Arm Versus the Control Arm in the PFS Intent to Treat (PITT) Populationprimary | Experimental Arm: Cabozantinib + Atezolizumab | 250 | 6.8 months | 0.63 | 0.0012 | link |
| Control Arm: Sorafenib | 122 | 4.21 months | ||||
| Overall Survival (OS) for the Experimental Arm Versus the Control Arm in the ITT Populationprimary | Experimental Arm: Cabozantinib + Atezolizumab | 432 | 16.46 months | 0.99 | 0.9056 | link |
| Control Arm: Sorafenib | 217 | 15.51 months |
Shares Exelixis, Cabozantinib, Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy.
Shares Immunotherapy downstaging to transplant with a safe washout, Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Anti-angiogenic therapy.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors.
Shares Exelixis, Cabozantinib, Atezolizumab, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Atezolizumab, Anti-angiogenic therapy, Hepatocellular carcinoma.
Shares Exelixis, Cabozantinib, Atezolizumab, Anti-angiogenic therapy.
Shares Immunotherapy downstaging to transplant with a safe washout, Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma, Immune checkpoint inhibitors.
Shares Advanced hepatocellular carcinoma (BCLC C), Anti-angiogenic therapy, Hepatocellular carcinoma, Small-molecule kinase inhibitors.